Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston
3
×
boston blog main
boston top stories
clinical trials
life sciences
national blog main
national top stories
san francisco blog main
3
×
new york blog main
rna interference
san diego blog main
san francisco top stories
akcea therapeutics
alexion pharmaceuticals
alnylam pharmaceutials
alnylam pharmaceuticals
arrowhead pharmaceuticals
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
barry greene
bluebird bio
boehringer ingelheim
boston university
dan ollendorf
deals
dicerna pharmaceuticals
drugs
duchenne muscular dystrophy
dyne therapeutics
eli lilly
facioscapulohumeral muscular dystrophy
fda
gene therapy
hepatitis b
hereditary transthyretin amyloidosis
indiana blog main
indiana top stories
What
ago
3
×
long
medicines
rna
abandoning
alnylam
approve
awaits
baggage
biological
biotechs
companies
considering
crossed
cuts
data
deal
decades
decision
development
dicerna
discovered
diseases
drug
dyne
early
expected
experimental
eyes
fda
fingers
free
friday
genetic
gets
having
historic
humans
interference
ipo
Language
unset
Current search:
boston
×
ago
×
" san francisco blog main "
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision